tuneTypical Dose
130 mg/day of free beta-sitosterol is the cleanest evidence-aligned BPH protocol
Natural Compound
Beta-Sitosterol
Beta-sitosterol
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Urinary symptom changes in BPH trials were assessed over weeks to months.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Beta-sitosterol has its clearest human evidence in BPH-related urinary symptoms, while cholesterol claims are better supported for mixed plant-sterol products than for purified beta-sitosterol alone.
Beta-sitosterol is marketed for both prostate and cholesterol support, but those use cases do not rest on equally strong evidence. For urinary symptoms due to benign prostatic enlargement, older randomized trials and a Cochrane review suggest meaningful symptom and flow improvements. For cholesterol lowering, the better evidence base belongs to mixed plant-sterol or plant-stanol products rather than to purified beta-sitosterol alone. Recent literature still leans heavily on mixed-phytosterol products or nonclinical work, so the standalone human evidence base for purified beta-sitosterol remains thin. That means beta-sitosterol is best framed as a low-confidence BPH symptom supplement, not as a stand-alone lipid therapy.
Beta-sitosterol is a plant sterol that may influence intestinal cholesterol handling and possibly prostate-related inflammatory or growth signaling. In practice, the clinically useful human data are more convincing for BPH symptom outcomes than for purified beta-sitosterol as a stand-alone lipid supplement.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Possible improvement in BPH-related urinary symptoms
- Possible improvement in peak urinary flow
Secondary Outcomes
- No convincing evidence that it reduces prostate volume
- Cholesterol claims are stronger for mixed plant-sterol products than for purified beta-sitosterol alone
Safety
Contraindications and Interactions
Contraindications
- Sitosterolemia
- Unexplained worsening urinary symptoms
Side effects
- Mild GI upset
Interactions
No entries provided
Avoid if
- You have sitosterolemia
- You are using it instead of evaluation for urinary symptoms
Evidence
Study-level References
bsit-SRC-001Systematic review
Sourceopen_in_newWilt TJ, Mac Donald R, Ishani A, Rutks I, Stark G. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001043. doi:10.1002/14651858.CD001043. PMID:10796740.
Population: Men with symptomatic benign prostatic hyperplasia enrolled in randomized trials of beta-sitosterol.
Dose protocol: Around 60 to 130 mg/day across included BPH trials
Key findings: Improved urinary symptoms, flow, and residual urine compared with placebo.
Notes: Main evidence anchor, but based on older short-term studies.
Paper content
This systematic review is the main evidence anchor for beta-sitosterol in BPH. It found meaningful improvements in urinary symptom scores and peak urinary flow compared with placebo, but the evidence base was small and short term. That supports low-confidence symptom relief for BPH-type symptoms, not a strong modern endorsement or proof of disease modification.
bsit-SRC-002Randomized controlled trial
Sourceopen_in_newKlippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol. 1997;80(3):427-432. PMID:9313662.
Population: Men with symptomatic bladder outlet obstruction due to benign prostatic hyperplasia.
Dose protocol: 130 mg/day for 6 months
Key findings: Improved symptoms and flow without reducing prostate size.
Notes: Best individual RCT for practical BPH framing.
Paper content
This placebo-controlled six-month trial gives beta-sitosterol a more concrete symptom-relief signal for BPH than most supplement records get. It showed better symptom scores, urinary flow, and residual-volume outcomes than placebo, but no meaningful change in prostate size. That matters because it supports symptomatic benefit without suggesting that beta-sitosterol reverses prostatic enlargement.
bsit-SRC-003Expert consensus panel position statement with systematic evidence review
Sourceopen_in_newGylling H et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346-360. PMID: 24468148.
Population: General population and individuals with dyslipidaemia, including those on statin therapy
Dose protocol: 2 g/day mixed plant sterols
Key findings: Strong LDL-lowering evidence exists for plant sterol mixtures.
Notes: Included only to clarify why mixed plant sterols should not be collapsed into purified beta-sitosterol claims.
Paper content
European Atherosclerosis Society Consensus Panel position statement concluded that plant sterols and stanols at 2 g/day reduce LDL-cholesterol by 8 to 10% through inhibition of intestinal cholesterol absorption. The panel endorsed their use as an adjunct to lifestyle changes in individuals with elevated LDL-cholesterol who do not yet qualify for pharmacotherapy, as an addition to statin therapy for patients who fail to reach LDL-cholesterol targets on statins alone, and for adults and children with familial hypercholesterolaemia. The panel noted that adding plant sterols or stanols to statin therapy provides additional LDL lowering equivalent to doubling the statin dose. Safety in the general population was affirmed, with the exception of individuals with sitosterolaemia. The panel acknowledged small reductions in plasma carotenoid concentrations and recommended adequate fruit and vegetable intake to compensate.
bsit-SRC-004Open extension of a multicenter double-blind placebo-controlled trial with 18-month follow-up
Sourceopen_in_newBerges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000;85(7):842-846. doi:10.1046/j.1464-410x.2000.00672.x. PMID:10792163.
Population: Men with symptomatic benign prostatic hyperplasia who completed the initial 6-month double-blind phase.
Dose protocol: Beta-sitosterol (Harzol) continued for up to 18 months after the initial 6-month double-blind phase
Key findings: Symptom improvements from the original 6-month RCT were maintained over 18 months of continued treatment. Patients who stopped showed minimal improvement.
Notes: Only long-term follow-up of beta-sitosterol for BPH. Open-label extension limits strength, but durability signal is useful.
Paper content
This 18-month open extension of the Klippel et al. double-blind RCT followed 117 men with symptomatic BPH. Patients who continued beta-sitosterol treatment maintained the symptom, flow, and quality-of-life improvements established during the original 6-month placebo-controlled phase. Those who stopped treatment showed minimal improvement. The results support durability of beta-sitosterol's symptomatic benefit but do not confirm disease modification.
bsit-SRC-005Double-blind, placebo-controlled, randomized comparative trial
Sourceopen_in_newSudeep HV, Thomas JV, Shyamprasad K. A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urol. 2020;20(1):86. doi:10.1186/s12894-020-00648-9. PMID:32620155.
Population: Males aged 40 to 65 years with symptomatic benign prostatic hyperplasia.
Dose protocol: 500 mg beta-sitosterol-enriched saw palmetto oil daily for 12 weeks versus conventional saw palmetto and placebo
Key findings: Beta-sitosterol-enriched formulation significantly improved IPSS, urinary flow rates, and aging male symptom scores versus placebo. Free testosterone also improved.
Notes: Uses a combination product (saw palmetto plus beta-sitosterol enrichment), so the independent contribution of beta-sitosterol is not fully isolated.
Paper content
This 12-week RCT compared beta-sitosterol-enriched saw palmetto oil, conventional saw palmetto oil, and placebo in 99 men with symptomatic BPH. The beta-sitosterol-enriched formulation showed significant improvements in IPSS, urinary flow rates, and aging male symptom scores versus placebo. Free testosterone also improved. The study suggests that beta-sitosterol enrichment adds meaningful value to saw palmetto for BPH symptom management.